Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Study to Evaluate Remdisivir in Combination with Old Rheumatoid Arthritis Drug Chloroquine in China

Trial Profile

A Clinical Study to Evaluate Remdisivir in Combination with Old Rheumatoid Arthritis Drug Chloroquine in China

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2020

At a glance

  • Drugs Chloroquine (Primary) ; Remdesivir (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 11 Mar 2020 New trial record

Trial Overview

Purpose

This clinical study will evaluate Remdisivir with the old rheumatoid arthritis (RA) drug chloroquine for the treatment of patients with coronavirus.

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections treatment -

Subjects

  • Subject Type patients
  • Sex male & female

Trial Details

Organisations

  • Sponsors Gilead Sciences
  • Affiliations Gilead Sciences

Trial Dates

Other Details

  • Design prospective
  • Phase of Trial Phase II
  • Location China
  • Focus Therapeutic Use

Interventions

Drugs Route Formulation
ChloroquinePrimary Drug
-
-
RemdesivirPrimary Drug Intravenous Infusion

Trial Centres

Centres

Centre Name Location Trial Centre Country
Gilead Sciences
-
-

Trial History

Event Date Event Type Comment
11 Mar 2020 New trial record New trial record Updated 11 Mar 2020

References

  1. Can-Fite BioPharma. Can-Fite Updates on Clinical Milestone for its Phase III Rheumatoid Arthritis Study with Piclidenoson; Drugs Combating Rheumatoid Arthritis are Currently Introduced for the Treatment of the Coronavirus. Media-Rel 2020;.

    Media Release
Back to top